178 related articles for article (PubMed ID: 24728960)
1. The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension.
Steriade A; Seferian A; Jaïs X; Savale L; Jutant EM; Parent F; Sitbon O; Humbert M; Simonneau G; Montani D
Ther Adv Respir Dis; 2014 Jun; 8(3):84-92. PubMed ID: 24728960
[TBL] [Abstract][Full Text] [Related]
2. Development of macitentan for the treatment of pulmonary arterial hypertension.
Selej M; Romero AJ; Channick RN; Clozel M
Ann N Y Acad Sci; 2015 Nov; 1358():68-81. PubMed ID: 26291180
[TBL] [Abstract][Full Text] [Related]
3. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience.
Belge C; Delcroix M
Ther Adv Respir Dis; 2019; 13():1753466618823440. PubMed ID: 30736726
[TBL] [Abstract][Full Text] [Related]
4. Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.
Jansa P; Pulido T
Am J Cardiovasc Drugs; 2018 Feb; 18(1):1-11. PubMed ID: 29280064
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
Dingemanse J; Sidharta PN; Maddrey WC; Rubin LJ; Mickail H
Expert Opin Drug Saf; 2014 Mar; 13(3):391-405. PubMed ID: 24261583
[TBL] [Abstract][Full Text] [Related]
6. Macitentan (Opsumit) for the treatment of pulmonary arterial hypertension.
Clarke M; Walter C; Agarwal R; Kanwar M; Benza RL
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):415-21. PubMed ID: 24851934
[TBL] [Abstract][Full Text] [Related]
7. [The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension].
Avdeev SN
Ter Arkh; 2016; 88(7):89-97. PubMed ID: 27459621
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
Sidharta PN; Krähenbühl S; Dingemanse J
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
[TBL] [Abstract][Full Text] [Related]
9. Macitentan: a review of its use in patients with pulmonary arterial hypertension.
Dhillon S
Drugs; 2014 Sep; 74(13):1495-507. PubMed ID: 25060980
[TBL] [Abstract][Full Text] [Related]
10. Macitentan for the treatment of pulmonary arterial hypertension.
Kholdani CA; Fares WH; Trow TK
Vasc Health Risk Manag; 2014; 10():665-73. PubMed ID: 25473292
[TBL] [Abstract][Full Text] [Related]
11. Macitentan for the treatment of pulmonary arterial hypertension.
DuBrock HM; Channick RN
Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329
[TBL] [Abstract][Full Text] [Related]
12. Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Pulido T; Adzerikho I; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Jing ZC; Le Brun FO; Mehta S; Mittelholzer CM; Perchenet L; Sastry BK; Sitbon O; Souza R; Torbicki A; Zeng X; Rubin LJ; Simonneau G;
N Engl J Med; 2013 Aug; 369(9):809-18. PubMed ID: 23984728
[TBL] [Abstract][Full Text] [Related]
13. New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension.
Martynyuk TV; Nakonechnikov SN; Chazova IY
Ter Arkh; 2018 Apr; 90(4):72-80. PubMed ID: 30701878
[TBL] [Abstract][Full Text] [Related]
14. Macitentan for the treatment of pulmonary arterial hypertension.
Hong IS; Coe HV; Catanzaro LM
Ann Pharmacother; 2014 Apr; 48(4):538-47. PubMed ID: 24458948
[TBL] [Abstract][Full Text] [Related]
15. [Endothelin: From discovery to pharmacotherapeutic innovations].
Richard V
Presse Med; 2014; 43(7-8):742-55. PubMed ID: 24797866
[TBL] [Abstract][Full Text] [Related]
16. Macitentan: A Review in Pulmonary Arterial Hypertension.
Keating GM
Am J Cardiovasc Drugs; 2016 Dec; 16(6):453-460. PubMed ID: 27580996
[TBL] [Abstract][Full Text] [Related]
17. Macitentan in the treatment of pulmonary arterial hypertension.
Zebadúa R; Hernández-Pérez AP; García A; Zayas N; Sandoval J; López J; Pulido T
Future Cardiol; 2021 Jan; 17(1):49-58. PubMed ID: 32677463
[TBL] [Abstract][Full Text] [Related]
18. The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study.
Chen Y; Luo J; Chen J; Kotlyar E; Li Z; Chen W; Li J
Front Pharmacol; 2021; 12():811700. PubMed ID: 35095523
[No Abstract] [Full Text] [Related]
19. Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension.
Krause A; Zisowsky J; Dingemanse J
Pulm Pharmacol Ther; 2018 Apr; 49():140-146. PubMed ID: 29501590
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension.
Souza R; Delcroix M; Galié N; Jansa P; Mehta S; Pulido T; Rubin L; Sastry BKS; Simonneau G; Sitbon O; Torbicki A; Boyanova N; Chamitava L; Stein C; Channick RN
Adv Ther; 2022 Sep; 39(9):4374-4390. PubMed ID: 35819570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]